CD80 and neoplasm: On the basis of our studies, we would predict that blocking CTLA-4 may promote intracellular CD80 and PD-L1 signals that may increase DC migration, and it is possible that in the clinic, this is a mechanism that affects the efficacy of CTLA-4 blockade in a tumor setting.